McAuliffe GN, Hennessy J, Baird RW, 2014. Relative frequency, characteristics and antimicrobial susceptibility patterns of Vibrio spp., Aeromonas spp., Chromobacterium violaceum, and Shewanella spp. in the northern territory of Australia, 2000ā2013. Am J Trop Med Hyg 92: 605ā610.
Whitman WB, Goodfellow M, KƤmpfer P, Busse H-J, Trujillo M, Ludwig W, Suzuki K-i & Parte A (eds), 2012. Bergey's Manual of Systematic Bacteriology. New York, NY: Springer-Verlag.
Yang CH, Li YH, 2011. Chromobacterium violaceum infection: a clinical review of an important but neglected infection. J Chin Med Assoc 74: 435ā441.
Yang CH, 2011. Nonpigmented Chromobacterium violaceum bacteremic cellulitis after fish bite. J Microbiol Immunol Infect 44: 401ā405.
Campbell JI, Lan NPH, Qui PT, Dung LT, Farrar JJ, Baker S, 2013. A successful antimicrobial regime for Chromobacterium violaceum induced bacteremia. BMJ Infectious Diseases 13: 4.
Cheong BM, 2010. A fatal case of pulmonary Chromobacterium violaceum infection in an adult. Med J Malaysia 65: 148ā149.
Hagiya H, Murase T, Suzuki M, Shibayama K, Kokumai Y, Watanabe N, Maki M, Otsuka F, 2014. Chromobacterium violaceum nosocomial pneumonia in two Japanese patients at an intensive care unit. J Infect Chemother 20: 139ā142.
Ke L, An KP, Heng S, Riley M, Sona S, Moore C, Parry C, Stoesser N, Chanpheaktra N, 2012. Paediatric Chromobacterium violaceum in Cambodia: the first documented case. Trop Doct 42: 178ā179.
Lim IW, Stride PJ, Horvath RL, Hamilton-Craig CR, Chau PP, 2009. Chromobacterium violaceum endocarditis and hepatic abscesses successfully treated with meropenem and ciprofloxacin. Med J Aust 190: 386ā387.
Huffam SE, Nowotny MJ, Currie BJ, 1998. Chromobacterium violaceum in tropical northern Australia. Med J Aust 168: 335ā337.
Baker S, Campbell JI, Stabler R, Nguyen HV, To DS, Nguyen DV, Farrer J, 2008. Fatal wound infection caused by Chromobacterium violaceum in Ho Chi Minh City, Vietnam. J Clin Microbiol 46: 3853ā3855.
Slesak G, Douangdala P, Inthalad S, Silisouk J, Vongsouvath M, Sengduangphachanh A, Moore CE, Mayxay M, Matsuoka H, Newton PN, 2009. Fatal Chromobacterium violaceum septicaemia in northern Laos, a modified oxidase test and post-mortem forensic family G6PD analysis. Ann Clin Microbiol Antimicrob 8: 24.
Seigal JK, Stadler ME, Lombrano JL, Almony JS, Couch ME, Belhorn TH, 2012. Chromobacterium violaceum necrotizing fasciitis: a case report and review of the literature. Ear Nose Throat J 91: 479ā483.
Richard K, Lovvorn J, Oliver S, Ross S, Benner K, Kong M, 2015. Chromobacterium violaceum sepsis: rethinking conventional therapy to improve outcome. Am J Case Rep 16: 740ā744.
Pant ND, Sharma M, Khatiwada S, 2015. Asymptomatic bacteriuria caused by Chromobacterium violaceum in an immunocompetent adult. Case Rep Med 2015: 652036.
Pant ND, Sharma M, 2015. Urinary tract infection caused by Chromobacterium violaceum. Int J Gen Med 2015: 293ā295.
Swain B, Otta S, Sahu KK, Panda K, Rout S, 2014. Urinary tract infection by Chromobacterium violaceum. J Clin Diagn Res 8: DD01āDD02.
Saboo AR, Vijaykumar R, Save SU, Bavdekar SB, 2015. A rare nonfatal presentation of disseminated Chromobacterium violaceum sepsis. J Microbiol Immunol Infect 48: 574ā577.
Kumar MR, 2012. Chromobacterium violaceum: a rare bacterium isolated from a wound over the scalp. Int J Appl Basic Med Res 2: 70ā72.
Madi DR, Vidyalakshmi K, Ramapuram J, Shetty AK, 2015. Case report: successful treatment of Chromobacterium violaceum sepsis in a south Indian adult. Am J Trop Med Hyg 93: 1066ā1067.
Karthik R, Pancharatnam P, Balaji V, 2012. Fatal Chromobacterium violaceum septicemia in a south Indian adult. J Infect Dev Ctries 6: 751ā755.
Ray P, Sharma J, Marak RS, Singhi S, Taneja N, Garg RK, Sharma M, 2004. Chromobacterium violaceum septicaemia from north India. Indian J Med Res 120: 523ā526.
Anah MU, Udo JJ, Ochigbo SO, Abia-Bassey LN, 2008. Neonatal septicaemia in Calabar, Nigeria. Trop Doct 38: 126ā128.
Bottieau E, Mukendi D, Kalo JR, Mpanya A, Lutumba P, Barbe B, Chappuis F, Lunguya O, Boelaert M, Jacobs J, 2015. Fatal Chromobacterium violaceum bacteraemia in rural Bandundu, Demographic Republic of Congo. New Microbes New Infect 3: 21ā23.
Al Khalifa SM, Al Khaldi T, Algahtani MM, Al Ansari AM, 2015. Two siblings with fatal Chromobacterium violaceum sepsis linked to drinking water. BMJ Case Rep 2015: pii bcr2015210987.
Arosio M, Raglio A, Ruggeri M, Serna Ortega P, Morali L, De Angelis C, Goglio A, 2011. Chromobacterium violaceum lymphadenitis successfully treated in a northern Italian hospital. New Microbiol 34: 429ā432.
Sivendra R, Tan SH, 1977. Pathogenicity of nonpigmented cultures of Chromobacterium violaceum. J Clin Microbiol 5: 514ā516.
Miller DP, Blevins WT, Steele DB, Stowers MD, 1988. A comparative study of virulent and avirulent strains of Chromobacterium violaceum. Can J Microbiol 34: 249ā255.
Podin Y, 2014. Burkholderia pseudomallei isolates from Sarawak, Malaysian Borneo, are predominantly susceptible to aminoglycosides and macrolides. Antimicrob Agents Chemother 58: 162ā166.
Pitman MC, Luck T, Marshall CS, Anstey NM, Ward L, Currie BJ, 2015. Intravenous therapy duration and outcomes in melioidosis: a new treatment paradigm. PLoS Negl Trop Dis 93: e0003586.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 64 | 64 | 13 |
Full Text Views | 369 | 100 | 1 |
PDF Downloads | 168 | 53 | 2 |
Chromobacterium violaceum is a bacterium associated with soil and water exposure in tropical regions and causes rare and serious clinical infections that are often fatal. We reviewed the demographic and clinical details of 28 patients with C. violaceum detected over 15 years from 2000 to 2015, from the Top End of the Northern Territory. Of these patients, 18 had infections attributable to C. violaceum. Patients with infections were more commonly male (55.6%), and in the 16- to 60-year (61.1%) age group. Skin and soft tissue infections (50%), predominantly involving the limbs, were the major clinical manifestation. Water, mud exposure, and trauma were all noted as precipitating circumstances and comorbidities were present in 61.1% of the patients with infections. Of the 28 patients, 10 (35.8%) had C. violaceum isolated as an incidental finding or as asymptomatic colonization; these 10 patients did not require or receive therapy for C. violaceum bacterial infections. There were no relapsing infections in this group. Chromobacterium violaceum remains a serious infection, with seven patients (25%) in our series requiring intensive care management. However, the mortality rate (7.1%) in our series was far lower than previously described. This case series of C. violaceum infections from a single geographic area provides additional information of the characteristics of infection with this pathogen.
Authors' addresses: Yi dan Lin, Department of Infectious Diseases, Royal Darwin Hospital, Darwin, Australia, E-mail: yidanl@gmail.com. Suman S. Majumdar, Centre for International Health, Burnet Institute, Victoria, Australia, E-mail: suman.majumdar@burnet.edu.au. Jann Hennessy and Robert W. Baird, Department of Microbiology, Royal Darwin Hospital, Darwin, Australia, E-mails: jann.hennessy@nt.gov.au and rob.baird@nt.gov.au.
McAuliffe GN, Hennessy J, Baird RW, 2014. Relative frequency, characteristics and antimicrobial susceptibility patterns of Vibrio spp., Aeromonas spp., Chromobacterium violaceum, and Shewanella spp. in the northern territory of Australia, 2000ā2013. Am J Trop Med Hyg 92: 605ā610.
Whitman WB, Goodfellow M, KƤmpfer P, Busse H-J, Trujillo M, Ludwig W, Suzuki K-i & Parte A (eds), 2012. Bergey's Manual of Systematic Bacteriology. New York, NY: Springer-Verlag.
Yang CH, Li YH, 2011. Chromobacterium violaceum infection: a clinical review of an important but neglected infection. J Chin Med Assoc 74: 435ā441.
Yang CH, 2011. Nonpigmented Chromobacterium violaceum bacteremic cellulitis after fish bite. J Microbiol Immunol Infect 44: 401ā405.
Campbell JI, Lan NPH, Qui PT, Dung LT, Farrar JJ, Baker S, 2013. A successful antimicrobial regime for Chromobacterium violaceum induced bacteremia. BMJ Infectious Diseases 13: 4.
Cheong BM, 2010. A fatal case of pulmonary Chromobacterium violaceum infection in an adult. Med J Malaysia 65: 148ā149.
Hagiya H, Murase T, Suzuki M, Shibayama K, Kokumai Y, Watanabe N, Maki M, Otsuka F, 2014. Chromobacterium violaceum nosocomial pneumonia in two Japanese patients at an intensive care unit. J Infect Chemother 20: 139ā142.
Ke L, An KP, Heng S, Riley M, Sona S, Moore C, Parry C, Stoesser N, Chanpheaktra N, 2012. Paediatric Chromobacterium violaceum in Cambodia: the first documented case. Trop Doct 42: 178ā179.
Lim IW, Stride PJ, Horvath RL, Hamilton-Craig CR, Chau PP, 2009. Chromobacterium violaceum endocarditis and hepatic abscesses successfully treated with meropenem and ciprofloxacin. Med J Aust 190: 386ā387.
Huffam SE, Nowotny MJ, Currie BJ, 1998. Chromobacterium violaceum in tropical northern Australia. Med J Aust 168: 335ā337.
Baker S, Campbell JI, Stabler R, Nguyen HV, To DS, Nguyen DV, Farrer J, 2008. Fatal wound infection caused by Chromobacterium violaceum in Ho Chi Minh City, Vietnam. J Clin Microbiol 46: 3853ā3855.
Slesak G, Douangdala P, Inthalad S, Silisouk J, Vongsouvath M, Sengduangphachanh A, Moore CE, Mayxay M, Matsuoka H, Newton PN, 2009. Fatal Chromobacterium violaceum septicaemia in northern Laos, a modified oxidase test and post-mortem forensic family G6PD analysis. Ann Clin Microbiol Antimicrob 8: 24.
Seigal JK, Stadler ME, Lombrano JL, Almony JS, Couch ME, Belhorn TH, 2012. Chromobacterium violaceum necrotizing fasciitis: a case report and review of the literature. Ear Nose Throat J 91: 479ā483.
Richard K, Lovvorn J, Oliver S, Ross S, Benner K, Kong M, 2015. Chromobacterium violaceum sepsis: rethinking conventional therapy to improve outcome. Am J Case Rep 16: 740ā744.
Pant ND, Sharma M, Khatiwada S, 2015. Asymptomatic bacteriuria caused by Chromobacterium violaceum in an immunocompetent adult. Case Rep Med 2015: 652036.
Pant ND, Sharma M, 2015. Urinary tract infection caused by Chromobacterium violaceum. Int J Gen Med 2015: 293ā295.
Swain B, Otta S, Sahu KK, Panda K, Rout S, 2014. Urinary tract infection by Chromobacterium violaceum. J Clin Diagn Res 8: DD01āDD02.
Saboo AR, Vijaykumar R, Save SU, Bavdekar SB, 2015. A rare nonfatal presentation of disseminated Chromobacterium violaceum sepsis. J Microbiol Immunol Infect 48: 574ā577.
Kumar MR, 2012. Chromobacterium violaceum: a rare bacterium isolated from a wound over the scalp. Int J Appl Basic Med Res 2: 70ā72.
Madi DR, Vidyalakshmi K, Ramapuram J, Shetty AK, 2015. Case report: successful treatment of Chromobacterium violaceum sepsis in a south Indian adult. Am J Trop Med Hyg 93: 1066ā1067.
Karthik R, Pancharatnam P, Balaji V, 2012. Fatal Chromobacterium violaceum septicemia in a south Indian adult. J Infect Dev Ctries 6: 751ā755.
Ray P, Sharma J, Marak RS, Singhi S, Taneja N, Garg RK, Sharma M, 2004. Chromobacterium violaceum septicaemia from north India. Indian J Med Res 120: 523ā526.
Anah MU, Udo JJ, Ochigbo SO, Abia-Bassey LN, 2008. Neonatal septicaemia in Calabar, Nigeria. Trop Doct 38: 126ā128.
Bottieau E, Mukendi D, Kalo JR, Mpanya A, Lutumba P, Barbe B, Chappuis F, Lunguya O, Boelaert M, Jacobs J, 2015. Fatal Chromobacterium violaceum bacteraemia in rural Bandundu, Demographic Republic of Congo. New Microbes New Infect 3: 21ā23.
Al Khalifa SM, Al Khaldi T, Algahtani MM, Al Ansari AM, 2015. Two siblings with fatal Chromobacterium violaceum sepsis linked to drinking water. BMJ Case Rep 2015: pii bcr2015210987.
Arosio M, Raglio A, Ruggeri M, Serna Ortega P, Morali L, De Angelis C, Goglio A, 2011. Chromobacterium violaceum lymphadenitis successfully treated in a northern Italian hospital. New Microbiol 34: 429ā432.
Sivendra R, Tan SH, 1977. Pathogenicity of nonpigmented cultures of Chromobacterium violaceum. J Clin Microbiol 5: 514ā516.
Miller DP, Blevins WT, Steele DB, Stowers MD, 1988. A comparative study of virulent and avirulent strains of Chromobacterium violaceum. Can J Microbiol 34: 249ā255.
Podin Y, 2014. Burkholderia pseudomallei isolates from Sarawak, Malaysian Borneo, are predominantly susceptible to aminoglycosides and macrolides. Antimicrob Agents Chemother 58: 162ā166.
Pitman MC, Luck T, Marshall CS, Anstey NM, Ward L, Currie BJ, 2015. Intravenous therapy duration and outcomes in melioidosis: a new treatment paradigm. PLoS Negl Trop Dis 93: e0003586.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 64 | 64 | 13 |
Full Text Views | 369 | 100 | 1 |
PDF Downloads | 168 | 53 | 2 |